Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial

Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401

(2012) William Kevin Kelly et al.   JOURNAL OF CLINICAL ONCOLOGY

Abstract A233: Cabozantinib (XL184), a dual MET-VEGFR2 inhibitor, blocks osteoblastic and osteolytic progression of human prostate cancer xenografts in mouse bone.

(2012) F. Schimmoller et al.   MOLECULAR CANCER THERAPEUTICS

VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer

(2011) W.-K. You et al.   CANCER RESEARCH

MET and VEGF: synergistic targets in castration-resistant prostate cancer

(2011) Dana T. Aftab et al.   Clinical & Translational Oncology

Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer

(2011) Razelle Kurzrock et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies

(2011) Timothy A. Yap et al.   JOURNAL OF CLINICAL ONCOLOGY

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

(2011) F. M. Yakes et al.   MOLECULAR CANCER THERAPEUTICS

Unknown

(2011) Minja Pfeiffer et al.   MOLECULAR MEDICINE

Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate

(2010) Alison H.M. Reid et al.   JOURNAL OF CLINICAL ONCOLOGY

Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells

(2010) Shumin Zhang et al.   Molecular Cancer

Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer

(2009) E. Y. Yu et al.   CLINICAL CANCER RESEARCH

Vascular endothelial growth factor regulates osteoblast survival – evidence for an autocrine feedback mechanism

(2009) John Street et al.   Journal of Orthopaedic Surgery and Research

A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer

(2008) W. L. Dahut et al.   CLINICAL CANCER RESEARCH